|Last Price||Today's Change||52-Week Range||Trading Volume|
|39.29||0.00 (0.00%)||30.05 - 52.33||0.0|
Market data as of 12:00AM 09/03/15. Quotes are delayed by at least 15 min.
Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation
08/17/2015 4:08 PM ET
Seattle Genetics Reports Second Quarter 2015 Financial Results
07/30/2015 4:02 PM ET